Changes in reimbursements for drugs for acid-related disorders
The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of heartburn, sour eructations and ulcers (‘acid-related disorders’) in order to assess whether they meet the criteria for public reimbursement.
We have decided that the medicinal products omeprazole, lansoprazole and pantoprazole should continue to be eligible for general reimbursement and that the reimbursement for the other medicinal products in this group should be removed. The reimbursement will be removed as patients may receive an equally effective treatment with omeprazole, lansoprazole and pantoprazole – but considerably cheaper.
Along with their patients, the general practitioners in Denmark must, by 15 November 2010, change or decide to change the treatment of patients being treated with the medicinal products which will lose their general reimbursement, if the patients are to continue to receive reimbursement for their treatment. For most patients, there will be no need to change their treatment – they are already being treated with omeprazole, lansoprazole or pantoprazole.
Find out more about the changes
Why is a review of reimbursements necessary?
Which medicines are affected by the reimbursement change?
You can still obtain reimbursement for your treatment
Financial implications of the changes
Changed reimbursement for drugs for acid-related disorders – background and importance
Decision by the Danish Medicines Agency – letters sent to companies